Committee Composition

  Audit Compensation and Management Development Nominating and Corporate Governance
Lewis T. "Rusty" Williams, M.D., Ph.D. Chairman of the Board      
Franklin M. Berger, CFA Committee Chair for Audit Committee   Member of Nominating and Corporate Governance Committee
Garry Nicholson Member of Audit Committee    
Sheila Gujrathi, M.D.   Committee Chair for Compensation and Management Development Committee  
Peder K. Jensen, M.D.   Member of Compensation and Management Development Committee Committee Chair for Nominating and Corporate Governance Committee

Dr. Jensen has served as a member of our board of directors since July 2011. Dr. Jensen is currently President of Bay Way Consultants, LLC, a consulting firm founded by Dr. Jensen in 2010 that advises pharmaceutical and biotechnology companies. Dr. Jensen has over 24 years of global drug development experience in both pharmaceutical and biotechnology companies and has been responsible for more than 40 new drug approvals in the U.S., Europe and Japan during his career. Dr. Jensen’s experience includes over 20 years with Schering- Plough Corporation, a global pharmaceutical company, and then Merck & Co., Inc. after the merger of Schering- Plough with Merck in 2009. Dr. Jensen most recently served at Schering-Plough as Corporate Senior Vice President, and General Manager, R&D for Japan and Asia/Pacific from 2006 to 2010. Dr. Jensen has also served at British Biotech plc and Chiron Corporation in clinical development executive positions and earlier in his career at CIBA-GEIGY Limited. Dr. Jensen is also a member of the board of directors of Acorda Therapeutics, Inc., a public biotechnology company. Dr. Jensen previously served as a member of the board of directors of BioCryst Pharmaceuticals, Inc., which was a public pharmaceutical company during Jensen's service as a director. Dr. Jensen received an M.D. degree from the University of Copenhagen, where he also completed his post-graduate medical training in neurology and internal medicine.


Mark D. McDade   Member of Compensation and Management Development Committee  
William R. Ringo Member of Audit Committee   Member of Nominating and Corporate Governance Committee
Chair of the Board = Chair of the Board Committee Chair = Chair Committee Member = Member

FPRX (Common Stock)

Exchange
NASDAQ
Price
20.89
Change (%)
0.00
Volume
N/A

Data as of 4:00 PM ET on Thursday, December 14, 2017
Minimum 20 minute delay
Refresh quote
Powered By eSignal, Inc.